avp

Potent and selective human vasopressin V1B receptor agonist (Ki values are 1.2, 151, 240 and 750 nM for V1B, V1A, Oxytocin and V2 receptors respectively). Stimulates ACTH and corticosterone secretion and exhibits negligible vasopressor activity in vivo.

Argipressin (Arg8-vasopressin) inhibits central corticotropin-releasing hormone. Argipressin acts as a repressor in the regulation of central CRH levels. 5A2-SC8 is an APC-dependent protein.

Vasopressin (argipressin), a cyclic nine-peptide synthesized by hypothalamic neurons, is one of the hormones involved in peptide prohormone synthesis. Vasopressin is involved in the regulation process of hypothalamic-pituitary-adrenal axis, increasing the amount of solute free water reabsorbed from the renal tubule's colate back into the circulation, narrowing arteries to increase pressure, enhancing the stimulating effect of corticotropin releasing factor to regulate pituitary corticotropin secretion. Vasopressin acts as a neurotransmitter during nerve conduction by binding to specific G-protein-coupled receptors.

(d(CH2)5[Tyr(Me)2, Dab5]AVP), a vasopressin V1a receptor-specific antagonist, demonstrates a pA2 value of 6.71 [1].

Selective vasopressin V1A receptor antagonist. Inhibits vasopressin and oxytocin-induced increases in intracellular calcium concentrations in vitro (IC50 values are 5 and 30 nM respectively). Exhibits potent and prolonged antivasopressor activity and indu

d[Cha4]-AVP TFA is a potent and selective agonist for the vasopressin (AVP) V1b receptor, with a high affinity (K i of 1.2 nM). It shows greater selectivity for the V1b receptor over the V1a receptor, V2 receptor, and oxytocin receptors, demonstrating specificity in targeting the human V1b receptor [1] [2].

[Pmp1,Tyr(OEt)2] AVP, a linear analog of the cyclic arginine vasopressin (AVP) antagonist, retains the antagonistic properties of its parent compound while featuring modified phenylalanine (Pmp) and diethyltyrosine (Tyr(OEt)2) components.

d[Cha4]-AVP acetate is a potent and selective human vasopressin V1B receptor agonist (Ki values are 1.2, 151, 240 and 750 nM for V1B, V1A, Oxytocin and V2 receptors respectively). Stimulates ACTH and corticosterone secretion and exhibits negligible vasopr

SKF 100398, also known as d(CH2)5Tyr(Et)VAVP, is a particular analog of arginine vasopressin (AVP). It acts as a specific antagonist, specifically targeting the antidiuretic effect caused by both exogenous and endogenous AVP.

Desmopressin (DDAVP)(DDAVP) is the synthetic analogue of the antidiuretic hormone arginine vasopressin.Vasopressin Receptor The antidiuretic properties of desmopressin have led to its use in polyuric conditions including primary nocturnal enuresis, nocturia, and diabetes insipidus. Desmopressin works by limiting the amount of water that is eliminated in the urine. Desmopressin binds to V2 receptors in renal collecting ducts, increasing water reabsorption. It also stimulates release of von Willebrand factor from endothelial cells by acting on the V2 receptor.

Desmopressin acetate (16679-58-6 free base) (DDAVP) is the synthetic analog of the antidiuretic hormone arginine vasopressin. Vasopressin Receptor The antidiuretic properties of desmopressin have led to its use in polyuric conditions including primary nocturnal enuresis, nocturia, and diabetes insipidus. Desmopressin acetate (16679-58-6 free base) works by limiting the amount of water that is eliminated in the urine. Desmopressin acetate (16679-58-6 free base) binds to V2 receptors in renal collecting ducts, increasing water reabsorption. It also stimulates the release of von Willebrand factor from endothelial cells by acting on the V2 receptor.

[Deamino-4-valine, 8-D-arginine]-Vasopressin (dVDAVP) is a highly potent and specific antidiuretic agent with prolonged effects [1] [2].

Argipressin, des-glynh2(9)-, can effect on aggregation of blood platelets.

Pneumadin, rat (PNM) exerts a marked antidiuretic effect in animals has a functional AVP system. Pneumadin, rat (PNM) is a decapeptide, which possesses a potent stimulating effect on arginine-vasopressin (AVP) release.

Argipressin (diacetate) (AVP (diacetate), also known as antidiuretic hormone (ADH)), is a nine-amino acid neuropeptide produced by the posterior pituitary gland. It plays a crucial role in maintaining fluid balance, osmolality, and cardiovascular function through interaction with three distinct G-protein coupled receptors (GPCRs): Avpr1a (V1a), Avpr1b (V1b), and Avpr2 (V2). Argipressin (diacetate) also influences centrally regulated metabolic processes, highlighting its significance in physiological regulation [1].

Desamino(D-3-(3′-pyridyl)-Ala2,Arg8)-Vasopressin, a synthetic analog of vasopressin (AVP), functions as a weak agonist at the antidiuretic receptor and a potent agonist at the pituitary corticotrope receptor [1].

Pro8-Oxytocin, a modified oxytocin (OXT) ligand, elicits more potent and efficacious responses at primate OXTR and induces stronger behavioral effects compared to the standard mammalian OXT ligand (Leu8-Oxytocin). It demonstrates lower efficacy than Vasopressin (AVP) at human AVPR1a, yet shows a higher efficacious response at marmoset AVPR1a [1].

Pro8-Oxytocin TFA, a modified oxytocin (OXT) ligand, exhibits greater potency and efficacy than the standard mammalian OXT ligand, Leu8-Oxytocin, at primate OXTR and elicits more pronounced behavioral effects. Compared to vasopressin (AVP), Pro8-Oxytocin TFA has a lower efficacious response at human AVPR1a, yet shows a higher efficacy at the marmoset AVPR1a [1].

[Deamino-Pen1,Val4,D-Arg8]-vasopressin (AVP-A) is an antagonist of arginine-vasopressin (AVP) that effectively reduces plasma aldosterone concentration in rats and is used to study the growth and steroidogenic capacity of the rat adrenal zona glomerulosa [1].

Potent, high affinity apelin receptor agonist (IC50 = 0.27 nM; Kd = 0.51 nM). Exhibits no binding GPR15 and GPR25. Activates the PI3K/AKT pathway and promotes self-renewal of hESCs via cell-cycle progression and protein translation. Also potentiates the T